Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 10/20 | 0.46 |
| ▸ | PRKDC | P78527 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.39 |
| ▸ | MTOR | P42345 | 11/20 | 0.39 |
| ▸ | ATR | Q13535 | 4/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | FECH | P22830 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | MELK | Q14680 | 1/20 | 0.35 |
| ▸ | MYLK3 | Q32MK0 | 1/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.35 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.35 |
| ▸ | TP53RK | Q96S44 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29969092 | 1.00 | ATM (0.46) | ATMPRKDCHPGDPIK3CAMTOR | |
| SCHEMBL29969038 | 0.89 | ATM (0.47) | ATMPRKDCPIK3CAMTORATR | |
| SCHEMBL29968542 | 0.86 | PRKDC (0.45) | ATMPRKDCHPGDPIK3CAMTOR | |
| SCHEMBL21513499 | 0.86 | PRKDC (0.45) | ATMPRKDCHPGDPIK3CAMTOR | |
| SCHEMBL21513256 | 0.82 | NPC1 (0.45) | ATMPRKDCHPGDPIK3CAMTOR | |
| SCHEMBL21513255 | 0.82 | MTOR (0.49) | ATMPRKDCPIK3CAMTORATR | |
| SCHEMBL29968579 | 0.82 | MTOR (0.49) | ATMPRKDCPIK3CAMTORATR | |
| SCHEMBL29968928 | 0.82 | NPC1 (0.45) | ATMPRKDCHPGDPIK3CAMTOR | |
| SCHEMBL21513286 | 0.81 | ATM (0.45) | ATMPRKDCPIK3CAMTORATR | |
| SCHEMBL29968839 | 0.81 | ATM (0.45) | ATMPRKDCPIK3CAMTORATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
| WO-2019201283-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | ATM 1/4885PRKDC 57/4885HPGD 1677/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | ATM 1/4885PRKDC 57/4885HPGD 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.